STAT June 20, 2024
The Food and Drug Administration on Thursday approved Elevidys, Sarepta’s gene therapy for Duchenne muscular dystrophy, for nearly all patients with the fatal muscle-wasting disease, dramatically expanding the initial, narrow authorization handed down last year.
The decision will likely be greeted by many families and doctors as a turning point in the fight against the muscle-wasting disease, even if it’s not nearly the seismic shift some had hoped for just a couple of years ago.
...Today's Sponsors
Today's Sponsor